» Articles » PMID: 22367168

Neuropeptide Y Y5 Receptor Antagonism Attenuates Cocaine-induced Effects in Mice

Overview
Specialty Pharmacology
Date 2012 Feb 28
PMID 22367168
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Several studies suggest a role for neuropeptide Y (NPY) in addiction to drugs of abuse, including cocaine. However, the NPY receptors mediating addiction-related effects remain to be determined.

Objectives: To explore the potential role of Y5 NPY receptors in cocaine-induced behavioural effects.

Methods: The Y5 antagonist L-152,804 and Y5-knockout (Y5-KO) mice were tested in two models of cocaine addiction-related behaviour: acute self-administration and cocaine-induced hyperactivity. We also studied effects of Y5 receptor antagonism on cocaine-induced c-fos expression and extracellular dopamine with microdialysis as well as dopamine transporter-mediated uptake of dopamine in vitro. Immunocytochemistry was used to determine whether dopamine neurons express Y5-like immunoreactivity.

Results: In self-administration, L-152,804 prominently decreased nose-poking for the peak dose of cocaine and shifted the dose-response curve for cocaine downward. Y5-KO mice also showed modestly attenuated self-administration. Cocaine-induced hyperactivity was attenuated by L-152,804 and in Y5-KO mice. Cocaine failed to increase c-fos expression in the nucleus accumbens and striatum of L-152,804-treated mice, indicating that the Y5 antagonist could act by influencing neural activity in these regions. Accordingly, the cocaine-induced increase in accumbal extracellular dopamine was attenuated by L-152,804 and in Y5-KO mice, suggesting that Y5 antagonism influences cocaine-induced behaviour by regulating dopamine. Consistent with this concept, dopamine neurons in the ventral tegmental area appeared to contain Y5 receptors. In contrast, neither L-152,804 nor NPY influenced dopamine transporter-mediated dopamine uptake.

Conclusions: The present data indicate that Y5 antagonism may attenuate cocaine-induced behavioural effects, suggesting that Y5 receptors could be a potential therapeutic target in cocaine addiction.

Citing Articles

Neuropeptides Modulate Feeding via the Dopamine Reward Pathway.

Jin R, Sun S, Hu Y, Zhang H, Sun X Neurochem Res. 2023; 48(9):2622-2643.

PMID: 37233918 DOI: 10.1007/s11064-023-03954-4.


Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards.

Dunigan A, Roseberry A Addict Neurosci. 2023; 2.

PMID: 37220637 PMC: 10201992. DOI: 10.1016/j.addicn.2022.100011.


Disruption of the PDZ domain-binding motif of the dopamine transporter uniquely alters nanoscale distribution, dopamine homeostasis, and reward motivation.

Sorensen G, Rickhag M, Leo D, Lycas M, Ridderstrom P, Weikop P J Biol Chem. 2021; 297(6):101361.

PMID: 34756883 PMC: 8648841. DOI: 10.1016/j.jbc.2021.101361.


The Role of Neuropeptide Y in the Nucleus Accumbens.

Tanaka M, Yamada S, Watanabe Y Int J Mol Sci. 2021; 22(14).

PMID: 34298907 PMC: 8307209. DOI: 10.3390/ijms22147287.


Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases.

Li C, Wu X, Liu S, Zhao Y, Zhu J, Liu K Front Neurosci. 2019; 13:869.

PMID: 31481869 PMC: 6710390. DOI: 10.3389/fnins.2019.00869.


References
1.
Sorensen G, Sager T, Petersen J, Brennum L, Thogersen P, Bengtsen C . Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology (Berl). 2008; 199(1):37-46. DOI: 10.1007/s00213-008-1069-z. View

2.
Josselyn S, Beninger R . Neuropeptide Y: intraaccumbens injections produce a place preference that is blocked by cis-flupenthixol. Pharmacol Biochem Behav. 1993; 46(3):543-52. DOI: 10.1016/0091-3057(93)90542-2. View

3.
Quarta D, Leslie C, Carletti R, Valerio E, Caberlotto L . Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology. 2010; 60(2-3):328-35. DOI: 10.1016/j.neuropharm.2010.09.016. View

4.
Walker M, Wolinsky T, Jubian V, Chandrasena G, Zhong H, Huang X . The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress.... J Pharmacol Exp Ther. 2008; 328(3):900-11. DOI: 10.1124/jpet.108.144634. View

5.
Tepper J, Tecuapetla F, Koos T, Ibanez-Sandoval O . Heterogeneity and diversity of striatal GABAergic interneurons. Front Neuroanat. 2011; 4:150. PMC: 3016690. DOI: 10.3389/fnana.2010.00150. View